This Article Full Text Full Text (PDF) Publisher's Note Erratum (v25,p3790) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Curran, D. Articles by Bonner, J. A. Search for Related Content PubMed PubMed Citation Articles by Curran, D. Articles by Bonner, J. A. Related Articles Related Editorial

Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab

Desmond Curran, Jordi Giralt, Paul M. Harari, K. Kian Ang, Roger B. Cohen, Merrill S. Kies, Jacek Jassem, José Baselga, Eric K. Rowinsky, Nadia Amellal, Sylvie Comte, James A. Bonner

From Omega Research, Dublin, Ireland; Radiation Oncology Service and Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Department of Human Oncology, University of Wisconsin, Madison, WI; Department of Radiation Oncology and Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Department of Medicine, University of Virginia, Charlottesville, VA; Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ImClone Systems, Branchburg, NJ; Merck KGaA, Darmstadt, Germany; and Department of Medicine, University of Alabama, Birmingham, AL

Address reprint requests to Desmond Curran, Omega Research, 189 Shanliss Rd, Santry, Dublin 9, Ireland; e-mail: descurran{at}omega-research.eu.com

Purpose: In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab.

Patients and Methods: Patients with stage III or IV nonmetastatic and measurable squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were eligible. QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EORTC QLQ Head and Neck Cancer–Specific Module at baseline, week 4, and at months 4, 8, and 12 postbaseline.

Results: In this study, one of the largest conducted in a population of patients with locoregionally advanced SCCHN, 424 patients received radiotherapy alone (213 patients) or radiotherapy plus cetuximab (211 patients). Radiotherapy/cetuximab significantly improved locoregional control (P = .005) and overall survival (P = .03) compared with radiotherapy alone, without significantly increasing radiotherapy-associated adverse events. The current analysis focused on the impact of cetuximab on the QoL. Compliance with completion of QoL questionnaires was high in both arms. QoL worsened during treatment and improved after cessation of treatment, reaching baseline levels at 12 months. There were no significant differences in QoL scores between the treatment arms. This was particularly notable for global health status/QoL, social functioning, social eating, and social contact. Pretreatment global health status/QoL was identified as a significant prognostic variable in these patients.

Conclusion: The addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without adversely affecting QoL.

Supported by Merck KGaA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer—More Insights, but More Questions
  Arlene A. Forastiere and Barbara A. Burtness
  JCO 2007 25: 2152-2155 [Full Text]

This article has been cited by other articles:

				J. A Bonner and J. J Caudell Combining Radiation with Biological Agents: Focus on the Inhibition of Epidermal Growth Factor Receptor Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 423 - 426. [Abstract] [Full Text] [PDF]

				L. K. Mell, R. R. Weichselbaum, J. A. Bonner, N. Azarnia, and E. K. Rowinsky More on Cetuximab in Head and Neck Cancer N. Engl. J. Med., November 22, 2007; 357(21): 2201 - 2203. [Full Text] [PDF]

				J. Li, S. M. Bentzen, M. P. Mehta, and M. Renschler In Reply J. Clin. Oncol., September 1, 2007; 25(25): 4024 - 4025. [Full Text] [PDF]

				A. A. Forastiere and B. A. Burtness Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer--More Insights, but More Questions J. Clin. Oncol., June 1, 2007; 25(16): 2152 - 2155. [Full Text] [PDF]